Tarsus Pharmaceuticals (NASDAQ:TARS) Director Sells $776,500.00 in Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) Director William Phd Link sold 12,500 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $62.12, for a total transaction of $776,500.00. Following the sale, the director directly owned 106,786 shares in the company, valued at $6,633,546.32. The trade was a 10.48% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tarsus Pharmaceuticals Price Performance

TARS stock opened at $63.16 on Friday. Tarsus Pharmaceuticals, Inc. has a twelve month low of $38.51 and a twelve month high of $85.25. The company has a quick ratio of 3.71, a current ratio of 3.74 and a debt-to-equity ratio of 0.21. The business has a 50 day moving average of $63.18 and a 200 day moving average of $69.38. The firm has a market cap of $2.72 billion, a PE ratio of -55.40 and a beta of 0.49.

Get Tarsus Pharmaceuticals alerts:

Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.24. The company had revenue of $162.05 million for the quarter, compared to analysts’ expectations of $149.60 million. Tarsus Pharmaceuticals had a negative net margin of 9.02% and a negative return on equity of 14.19%. On average, research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -0.59 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on TARS shares. Zacks Research cut shares of Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. HC Wainwright reaffirmed a “buy” rating and set a $88.00 price objective on shares of Tarsus Pharmaceuticals in a research report on Monday, May 4th. Wall Street Zen downgraded shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday. Lifesci Capital raised shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Monday, March 16th. Finally, Guggenheim raised their price objective on Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $90.67.

Check Out Our Latest Report on TARS

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Rockefeller Capital Management L.P. grew its holdings in shares of Tarsus Pharmaceuticals by 15.5% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock worth $105,000 after purchasing an additional 172 shares during the last quarter. Parallel Advisors LLC increased its holdings in Tarsus Pharmaceuticals by 139.2% during the first quarter. Parallel Advisors LLC now owns 500 shares of the company’s stock valued at $35,000 after buying an additional 291 shares during the period. State of Wisconsin Investment Board raised its position in shares of Tarsus Pharmaceuticals by 1.1% in the 4th quarter. State of Wisconsin Investment Board now owns 31,912 shares of the company’s stock worth $2,613,000 after acquiring an additional 332 shares in the last quarter. Federated Hermes Inc. raised its holdings in Tarsus Pharmaceuticals by 0.6% in the second quarter. Federated Hermes Inc. now owns 55,021 shares of the company’s stock worth $2,229,000 after purchasing an additional 339 shares in the last quarter. Finally, Valeo Financial Advisors LLC raised its stake in shares of Tarsus Pharmaceuticals by 11.1% during the 4th quarter. Valeo Financial Advisors LLC now owns 3,915 shares of the company’s stock worth $321,000 after acquiring an additional 392 shares in the last quarter. Institutional investors own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

(Get Free Report)

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.

Featured Stories

• Five stocks we like better than Tarsus Pharmaceuticals
• Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself?
• Rackspace’s AI Land Grab: Plugging Into the Next Compute Boom
• Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore
• Why Kroger’s Pullback Could Be a Gift for Patient Investors

Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.